Drug intelligence / Profile preview

TriAd

Development stage: Unknown
Lead developer: ImmunityBio
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

TriAd is a trivalent therapeutic cancer vaccine cocktail consisting of three distinct second-generation (E1-, E2b-deleted) adenovirus type 5 (Ad5) vectors, each encoding a different tumor-associated antigen: Carcinoembryonic Antigen (CEA; ETBX-011), Mucin 1 (MUC1; ETBX-051), and Brachyury (ETBX-061). Developed by ImmunityBio, the vaccine platform is designed to overcome pre-existing Ad5 immunity and induce robust Th1-mediated T-cell responses against multiple targets simultaneously. It is frequently evaluated in combination with other immunotherapies, such as the IL-15 superagonist N-803 (Anktiva) and the PD-L1/TGF-beta trap bintrafusp alfa (M7824), for the treatment of various solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, and chordoma.

Other names: TriAd vaccineAdenoviral vector vaccine TriAd

Targets

CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)MUC1 (Mucin-1 Antigen)T (Brachyury transcription factor)

Beyond the preview

Go deeper on TriAd.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TriAd.

Explore the full profile